Overview
WUXI XDC (2268)
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europ...
- Open
- 69.000
- High
- 69.450
- Low
- 67.500
- Prev. Close
- 69.350
- Volume
- 2.96M
- Turnover
- 201.96M
- Avg Price
- 68.219
- Bid/Ask Ratio
- -57.89%
- Amplitude
- 2.81%
- 52wk High
- 85.600
- Volume Ratio
- 0.38
- Turnover Ratio
- 0.23%
- 52wk Low
- 43.500
- HK Mkt Cap
- 86.68B
- Market CapHKD
- 86.68B
- P/ETTM
- 48.44
- P/EDynamic
- 45.95
- P/EStatic
- --
- EPSTTM
- 1.41
- EPSDynamic
- 1.48
- EPSStatic
- --
- BVPS
- 10.23
- P/B
- 6.66
- HK Shares
- 1.27B
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 1.27B
- Min lot size
- 500
- Currency
- HKD
WUXI XDC Analyst Rating
View moreForecast & Rating
Nov 13, 2026- Strong buy71.43%
- Buy28.57%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 15
- Buy
- 6
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 11
WuXi XDC fell 2.9% to HK$71.00 in a spike-and-fade session: it touched HK$73.15 at 09:39 BJ before sliding to HK$69.20 by 10:56, then recovered to HK$71.85 in the afternoon, on HK$536 million turnover. The pullback reflects broad pressure on the innovative-drug sector plus profit-taking after a sharp run that included a 12% single-day jump and a 52-week high of HK$85.60. Fundamentals contrast with the tape: Q2 2026 revenue rose 44.5% yoy to HK$2.14 billion and operating profit 50.7% to HK$633 million, while net profit grew only 15.8% to HK$473 million, leaving a 22.1% net margin and 14.5% ROE. At HK$71.00 the stock trades at 50.4x PE and 6.94x PB on a HK$90.2 billion market cap with turnover of just 0.59%. It is up 15.7% year-to-date yet still 17.1% below its 52-week high and below both MA20 (HK$71.11) and MA60 (HK$74.69). Though a Goldman Sachs upgrade and block trades drove a 3% gain earlier and most brokers rate it buy, momentum looks fragile.
- Nov, 4
Expectations that Democrats could control both chambers after the US midterms ignited the biotech complex: the Hong Kong biotech index jumped nearly 8% in the afternoon session, and WuXi XDC reversed from a HK$63.90 open to trend higher all afternoon and close at HK$71.95, up 13.5%, travelling from an intraday low of HK$63.60 to HK$72.00 at the close on HK$444 million turnover, while Guosheng Securities highlighted China's pharma innovation efficiency and the AI-enabled value chain the same day. Second-quarter revenue rose 44.46% year on year to HK$2.14 billion and operating profit 50.71%, but net profit grew only 15.81% to HK$473 million, leaving earnings behind the top line. The shares are up 17.28% year to date yet sit 15.95% below the 52-week high of HK$85.60 and under both MA20 (HK$73.73) and MA60 (HK$74.01), though the PE is 51.1x and the stock fell 4.23% last week.
- Nov, 3
WuXi XDC fell 3.86% to HK$63.50 as the life sciences index slipped for a fourth straight session and BeOne and WuXi AppTec each dropped about 3%, with the stock opening at HK$65.95, reversing, and testing HK$61.65 in the afternoon before paring losses on HK$372.3 million turnover and a 0.47% turnover rate. The session range was HK$61.65 to HK$65.25. The move extends a weak stretch for innovative-drug names, after the shares had previously fallen 8% in a single session; UBS still described China’s CRO sector as resilient in Q3 and pointed to backlog momentum. Fundamentals contrast with the tape: Q2 revenue rose 44.46% year on year to HK$2.14 billion, operating profit climbed 50.71% to HK$633 million, net profit gained 15.81% to HK$473 million, EPS rose 10.96% to HK$0.3465 and net margin was 22.13%. Even so, at a HK$80.7 billion market cap, 45.1x PE and 6.2x PB, the price sits below its MA20 of HK$74.34 and MA60 of HK$73.85, 25.82% below the 52-week high of HK$85.60 and up only 3.50% year to date, though still 45.98% above the 52-week low of HK$43.50.
- Oct, 23
WuXi XDC reversed an early slide to close at HK$71.50, up about 3.8% from HK$68.90, after dipping to HK$66.45 in the morning session and rallying to HK$71.80 in the afternoon on HK$806 million turnover, as UBS flagged resilient Q3 demand for China's CRO sector with focus on backlog momentum and Goldman Sachs kept a growth view on mainland CRO/CDMO while lifting its average target price by about 9%; several large cross trades also printed. Fundamentals back the move: Q2 2026 revenue of HK$2.14 billion rose 44.46% yoy, operating income HK$633 million up 50.71%, net profit HK$473 million up 15.81% and net margin 22.13%. Yet the shares still sit below MA20 at HK$78.80 and MA60 at HK$72.34, 16.47% under the 52-week high of HK$85.60 despite a 16.54% YTD gain, with PE 50.77x and PB 6.98x, while the stock fell 11.1% last week.
- Oct, 22
WuXi XDC closed down about 9% at HK$69.30 on Thursday, as broad pressure across the innovative drug sector drove profit-taking in the ADC outsourcing leader; the stock opened flat, briefly touched HK$76.95, then drifted steadily lower through the afternoon session to an intraday low of HK$68.60 at 15:07 BJ, on roughly HK$628 million turnover and a 0.69% turnover rate. Fundamentals sit at odds with the tape: Q2 2026 revenue reached HK$2.138 billion, up 44.46% year on year, and operating income HK$633 million, up 50.71%, yet net profit of HK$473 million grew only 15.81% with a 22.13% net margin, leaving the shares at 49.21x PE and 6.77x PB on an HK$88.0 billion market cap. Price positioning is stretched to the downside against the moving averages: the close sits below both the MA20 of HK$79.24 and the MA60 of HK$72.03, 19.04% under the 52-week high of HK$85.60 set on October 11, while still up 12.96% year to date. Goldman Sachs had earlier raised its average target price for the mainland China CRO/CDMO sector by 9%, though continued sector outflows kept the rebound from holding.
News
Weekly Review · Weekly Recap | WUXI XDC -2.94%, most brokers rate it buy
Weekly Review · Weekly Recap | WUXI XDC +6.89%, most brokers rate it buy
Market Movers · WuXi XDC surges 12% in Hong Kong trading
Global Report · Niche Consolidation: Hong Kong's Specialty Leaders Forge Growth Paths Amid Fragmentation
Global Report · A USD 90 Million Upfront Anchors Hong Kong Biotech's December Rush
Weekly Review · Weekly Recap | WUXI XDC -4.23%, consensus target above spot
